Demil

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Demil

Quick Facts

Property Description
Active ingredient Bromocriptine
Form Tablets or Capsules
Pharmacological class Dopamine Receptor Agonist, Ergot Alkaloid Derivative
General purpose Correcting hormonal and neurological imbalances
Origin Semisynthetic

What Type of Medicine is Demil (Bromocriptine)?

Demil is the trade name for the active pharmaceutical ingredient Bromocriptine, which belongs to the distinct pharmacological class of dopamine receptor agonists. It functions as a neuroendocrine modulator and is further classified as a semisynthetic ergot alkaloid derivative, delivered as a single-ingredient product. Bromocriptine is prepared for oral ingestion in the form of solid pharmaceutical preparations, specifically tablets or capsules, making it suitable for systemic delivery.

General Purpose and Primary Physiological Action

The core purpose of Demil is to manage physiological conditions arising from imbalances concerning the hormone prolactin and the brain chemical dopamine. Bromocriptine acts as an agonist, meaning it mimics natural dopamine to stimulate specific dopamine receptors (D₂ receptors). This central action leads directly to the inhibition of prolactin secretion from the pituitary gland. The general benefit is the restoration of hormonal and neurological equilibrium, a function utilized in managing conditions related to excessive prolactin or compromised dopamine signaling.

Why is Bromocriptine Classified as an Ergot Derivative?

Bromocriptine is defined as an ergot derivative because its chemical structure is semisynthetic, meaning it is manufactured based on a natural precursor found in the ergot fungus, specifically the alkaloid ergocryptine. This heritage sets it apart from purely synthetic drugs in the same class. The compound's origin and structure are integral to its ability to function as a centrally acting modulator, influencing neuroendocrine feedback loops within the body, a distinction that characterizes its binding affinity and duration of action.

Regulatory References

  1. MedlinePlus

What side effects are possible with Demil?

Possible Side Effects and Safety Information

The official safety profile for Demil (Bromocriptine) is structured around categories of side effects, timing of occurrence, and population-specific considerations, as documented in regulatory sources like the FDA and EMA.

Adverse Reactions Classified by Frequency

Adverse reactions are formally classified by the frequency observed in clinical studies and post-marketing surveillance. Nausea, headache, dizziness, and fatigue are among the most frequently reported initial reactions, often classified as Most Common or Common. Other common effects include vomiting, constipation, and orthostatic hypotension (a drop in blood pressure upon standing). Less common effects include hallucinations, confusion, and dry mouth.


Systemic Safety Patterns and Serious Risks

Adverse reactions are grouped by the affected system. The most frequently involved systems are Gastrointestinal and Nervous System disorders. The official label also documents risks to the Vascular and Cardiac Systems. The label for this class of medicine notes the potential for Impulse Control Disorders, such as pathological gambling and hypersexuality.

Serious Adverse Reactions reported in post-marketing experience include rare events like stroke, myocardial infarction (heart attack), and seizures. Furthermore, the risk of pleural, pulmonary, or retroperitoneal fibrosis is associated with prolonged, high-dose administration.


Time-Related and Population-Specific Safety

Certain effects are linked to the timing of treatment. Orthostatic hypotension and syncope are most likely to occur at the start of therapy or following dose increases. Conversely, fibrotic risks are associated with long-term exposure. Regulatory safety constraints include the explicit contraindication of this medicine for the suppression of lactation in postpartum women with uncontrolled hypertension or specific cardiovascular risks, due to reports of serious adverse events in this population.

Overdose and Emergency Response

Demil Overdose and when to seek help

Overdose of Demil (Bromocriptine) is characterized by a specific set of documented clinical manifestations affecting the central nervous system, gastrointestinal system, and cardiovascular stability.

The core documented overdose presentations include severe physical findings such as Severe Hypotension (profoundly low blood pressure), alongside CNS effects like Confusion, Lethargy, Somnolence, Delusions, and Hallucinations. Other reported symptoms are Nausea, Vomiting, Dizziness, Pallor, and Repetitive Yawning.

When to Seek Immediate Medical Help

Regulatory documents state that immediate medical attention must be sought for any suspected overdose or for the presence of the severe symptoms listed above. Hospital monitoring is required due to the risk of profound cardiovascular instability and altered consciousness. Accidental ingestion cases have been reported, with a high proportion involving children.

Official Management and Antidote Status

Management is officially defined as symptomatic and supportive. Procedures mandated by regulatory authorities to limit drug absorption include Gastric Lavage or administration of Activated Charcoal. Treatment for severe hypotension requires specific steps, such as placing the patient in the Trendelenburg position and administering Intravenous Fluids, with Vasopressors considered if relief is unsatisfactory. No specific antidote is known for Bromocriptine overdose. Careful supervision and recording of fluid intake and output is essential.

Therapeutic Uses of Demil

What Demil Treats: Main Uses and Benefits

Demil (Bromocriptine) is considered relevant across several therapeutic domains. It is applied in clinical settings where supportive symptom management is appropriate. The medication may be part of symptomatic management for conditions like hyperprolactinemia (including prolactin-secreting pituitary tumors), Parkinson’s disease, Acromegaly, and Type 2 Diabetes Mellitus.

Endocrine and Neurological Support

This domain helps address symptom clusters related to systemic imbalance from hyperprolactinemia, such as amenorrhea (absent periods), galactorrhea, and associated infertility. It supports patients during episodes of heightened discomfort. In neurological contexts, it is applied to ease symptoms of increased neurological or muscular activity in Parkinson's, helping to manage rigidity and tremor. It contributes to easing the overall symptom load during periods when symptoms interfere with daily functioning.


Quick Fact: Focus on Key Symptom Domains
Hormonal: Assists with symptoms of systemic imbalance from high prolactin.
Motor: May assist with symptoms of increased neurological or muscular activity, such as rigidity and slowness of movement.
Metabolic: Is commonly used to help with managing symptoms that create noticeable physiological strain in metabolic health.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Demil?

The population eligibility for Demil (Bromocriptine) is strictly defined by official regulatory documentation, primarily based on the patient's existing health conditions and physiological status.

Eligibility Status

Category Regulatory Status Constraint
Adults Allowed Eligible for all approved indications.
Pediatric (Under 16) Not Established Safety and efficacy have not been established for most indications in children younger than 16 years, with limited data for adolescents with prolactin-secreting tumors.
Older Adults Conditional Use Use is allowed, but caution is advised due to potential increased sensitivity and greater frequency of age-related organ function decrease.
Nursing Women Contraindicated Use is prohibited as the medication inhibits lactation.
Pregnancy Restricted Generally advised to discontinue upon confirmation of pregnancy, unless medically necessary for conditions such as an expanding pituitary macroadenoma.

Absolute Contraindications

Demil must not be used in the following patient populations, as strictly defined by regulatory agencies:

  • Patients with known hypersensitivity to Bromocriptine or other ergot alkaloids.
  • Patients with uncontrolled hypertension (high blood pressure) or a history of severe cardiovascular conditions.
  • Women with hypertensive disorders of pregnancy (e.g., eclampsia, pre-eclampsia, or postpartum hypertension).
  • Patients with a history of severe psychotic disorders or syncopal migraines.

Condition-Specific Restrictions

  • Use requires caution in patients with hepatic (liver) impairment due to the drug's metabolism.
  • The medication is not for the treatment of Type 1 Diabetes Mellitus or diabetic ketoacidosis.

What should I know about interactions with other medicines?

The official interaction profile for Demil (Bromocriptine) is structured around its primary metabolic pathway and its role as an ergot derivative, defining specific use restrictions.

Co-administration with strong CYP3A4 inhibitors (such as azole antimycotics and certain HIV protease inhibitors) is formally contraindicated due to the significant risk of increased bromocriptine plasma concentrations. Similarly, combination with Triptans (e.g., Sumatriptan) is contraindicated because of the potential for additive vasoconstrictive effects, and Triptans must not be used within 24 hours of Demil administration. Other ergot-related drugs for migraine are not recommended within 6 hours of dosing.

Bromocriptine is extensively cleared by the CYP3A4 enzyme. Inhibitors of this enzyme increase systemic exposure, while inducers may reduce it. This is why official labeling advises a dose restriction during concomitant use with a moderate CYP3A4 inhibitor (e.g., Erythromycin).

Dopamine Receptor Antagonists (including certain neuroleptic agents and Metoclopramide) are not recommended as they may mutually diminish the effectiveness of both drugs. Co-administration with antihypertensive medications may result in an additive hypotensive effect.

Alcohol and Grapefruit Juice should be avoided; alcohol may potentiate side effects, and grapefruit juice may significantly increase drug concentrations due to CYP3A4 inhibition. Liver Impairment is noted as a condition that may increase plasma levels, potentially intensifying interaction risks.

Mechanism of Action

Receptor-Mediated Antagonism

Demil (Diphemanil Methylsulfate) is an anticholinergic agent that modulates signaling within the parasympathetic nervous system. It acts within domains involving receptor-mediated signaling by functioning as a muscarinic acetylcholine receptor antagonist. Demil specifically binds to and blocks muscarinic receptors on target cells, preventing the endogenous neurotransmitter acetylcholine from binding. This molecular blockade initiates the subsequent mechanistic cascade.


Modulation of Parasympathetic Pathway Activity

The drug modulates key pathways associated with efferent activity of the parasympathetic nervous system. By blocking acetylcholine's effects, Demil initiates a cascade that suppresses signaling sequences typically driven by parasympathetic nerve impulses. This influence modifies efferent nervous system output, altering targeted physiological functions.


Modification of Smooth Muscle and Secretion

The resulting physiological consequence of Demil's action involves modification of targeted organ responses. By engaging mechanisms that regulate cholinergic signaling, the mechanism results in smooth muscle relaxation in specific organs and a reduction in gland secretions, modifying the state within the targeted physiological systems.

Dosage and Administration Information

Demil (bromocriptine) is administered exclusively through the oral route, available in immediate-release tablets or capsules. The central principle for its use across most conditions, including hyperprolactinemia and Parkinson’s disease, is gradual dose titration. Treatment initiates with a low dose, such as 1.25 mg once daily or twice daily, which is systematically increased at specific intervals until the appropriate daily regimen is established. The maintenance dose range varies significantly by indication, with prescribed doses potentially reaching up to 30 mg/day for conditions like acromegaly.


Administration Conditions

Dosing Principle Detail
Initial Use Starts low, with gradual weekly increments (titration).
Intake Condition Always taken with food to enhance tolerability and absorption.
Frequency Pattern Typically involves divided doses daily (BID or TID) for maintenance, though some initial regimens are once daily.

For the specialized 0.8 mg tablet used in Type 2 Diabetes Mellitus, the administration protocol is strictly once daily and must occur specifically within two hours after waking. For most long-term indications, the dose should not be stopped suddenly. If a dose of the specialized diabetes tablet is missed, the standard protocol is to skip that dose rather than doubling the next day’s intake. Dose adjustments for specific populations are detailed; for instance, treatment in older adults should generally begin at the lower end of the dosing range, and specific maximum doses are defined for pediatric patients.

Recent Clinical Evidence

Demil (bromocriptine) is considered relevant across several long-term health conditions, with research ranging from historical trials to recent large-scale studies. The following overview details the types of research conducted and the patterns observed, focusing only on the available evidence without providing personal advice or clinical instructions.

Evidence for Use in High Prolactin Conditions (Hyperprolactinemia)

Research into Demil's use for hyperprolactinemia has included Randomized Controlled Trials (RCTs), comparative systematic reviews, and long-term observational studies. Studies primarily focused on biomarker changes, such as measuring the normalization of high serum prolactin concentrations. Long-term observational findings generally described reductions in measured tumor size over time. However, comparative systematic reviews indicate that other similar medicines may be observed with different efficacy or tolerance patterns in comparative evidence. What remains uncertain is the long-term durability of hormonal control after the medicine is stopped.

Evidence for Use in Parkinson’s Disease

The evidence base for Demil in Parkinson's disease is founded on numerous RCTs. These studies were used in research exploring how symptoms change over time and monitored outcomes reflecting daily functioning or activity level using standardized motor scales. Comparative findings with levodopa were varied; some studies described similar measurements of impairment and disability. Limited information for long-term outcomes beyond a few years is available, and some extended follow-up studies described a gradual late fall-off in effect.

Evidence for Use in Type 2 Diabetes Mellitus

Research for the use of Demil in Type 2 Diabetes Mellitus has centered on a specific quick-release formulation. The evidence consists of large RCTs that monitored outcomes related to systemic or functional imbalance, specifically looking at changes in Glycated Hemoglobin (HbA1c). Studies reported measurements showing a reduction in both HbA1c and FPG from baseline levels. Furthermore, some analysis described a pattern of reduction in the relative risk of major composite cardiovascular events over the 52-week study period, compared to placebo. Follow-up durations were limited primarily to one year, and the long-term sustainability of the observed patterns is not fully established.

Key Studies & References Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes (Cycloset Safety Trial)

Frequently Asked Questions (FAQ)

Common questions about Demil (FAQ)


Q: Can Demil affect a person's sleep patterns?

Official documents describe that changes in sleep patterns may be experienced by some users. These changes can include difficulty falling or staying asleep (insomnia). Conversely, official information also notes that feelings of unusual tiredness or drowsiness (somnolence) are reported. Furthermore, the prescribing information mentions reports of sudden onset of sleep, particularly in patients using the medication for Parkinson’s disease.


Q: What should I know about combining Demil with common over-the-counter pain relievers?

The official product label does not specify a contraindication or direct interaction with common over-the-counter pain relievers like acetaminophen. However, regulatory guidance consistently advises disclosing all over-the-counter medicines to a healthcare professional. This is important in order to review potential contraindications or overlapping effects with any component of the non-prescription medicine.


Q: Is it safe to use Demil while drinking coffee or caffeine products?

The official product label does not specifically list an interaction with caffeine. However, Demil is known to cause central nervous system effects, such as dizziness and somnolence (drowsiness). Because caffeine is a stimulant, official prescribing information generally advises caution regarding concurrent use of central nervous system stimulants.


Q: Are there any specific vitamins or supplements that should not be taken with Demil?

Official prescribing information advises caution with all supplements and herbal products. Specifically, the drug's metabolism involves a liver enzyme called CYP3A4. Therefore, any supplement known to strongly affect this enzyme, such as certain herbs or high-dose vitamins, is typically disclosed to a healthcare professional for review.


Q: If I miss a use of Demil, what is the general guidance on how to proceed?

The guidance for a missed use depends on the specific formulation being used. For the specialized tablet used in Type 2 Diabetes Mellitus, official instructions specify that the missed dose should be skipped rather than taking extra the next day. Guidance for other uses is generally determined on an individual basis by a healthcare professional.


Q: Is it normal to feel a change in appetite when starting Demil?

Official prescribing information lists loss of appetite, medically referred to as anorexia, as an adverse reaction that has been reported by patients. This means that feeling a change in appetite can occur, although it is not considered one of the most frequently reported side effects.


Q: Can a person take Demil if they are already on several other chronic medications?

The official documentation identifies many specific categories of prescription and non-prescription medications that can interact with Demil. These include certain heart or blood pressure medicines and other dopamine-affecting agents. Regulatory guidance suggests a healthcare professional review all concurrent medications for potential interaction risks.


Q: Can Demil be used by people with known kidney issues?

The safety and effectiveness of Demil in patients with severe renal (kidney) disease have not been fully established in regulatory studies. While official guidance generally does not recommend a specific dose adjustment for kidney impairment, caution may be advised when the product is used in patients with pre-existing conditions.


Q: Does taking Demil affect the results of routine lab tests?

While the drug is used to manage and normalize specific biomarkers, such as prolactin and HbA1c, the official labeling does not indicate that the medication causes false positive or false negative results on general, routine laboratory tests that are not related to the drug's purpose.


Q: Are there any restrictions on driving or operating machinery while using Demil?

The official warnings advise patients to avoid driving or operating hazardous machinery until they are aware of how the medication affects them. This guidance is based on the potential for side effects like dizziness, fatigue, and somnolence (drowsiness). This precaution is related to the potential for impaired response, depending on individual reaction.


Q: What are the most commonly reported reasons for discontinuing Demil?

The most common adverse reactions reported by patients, which are often the primary reasons for discontinuation, include nausea, headache, dizziness, and fatigue. Official safety information also notes that certain symptoms, such as apathy, anxiety, depression, and fatigue, may be experienced if the medication is stopped abruptly.


Q: Does Demil have any known interactions with herbal supplements like St. John's Wort?

Official prescribing information does not list St. John's Wort as a strictly contraindicated supplement, but it does advise against using strong inhibitors or inducers of the CYP3A4 enzyme. Because St. John's Wort is commonly known to affect this enzyme system, its use is typically disclosed to a professional for review.


Q: What is the typical timeframe for seeing the full described effect of Demil?

The timeframe for observing the full described effect is highly dependent on the specific condition being treated. While some clinical studies monitored results over periods as long as 52 weeks, hormonal effects may be measured sooner. The appropriate duration of use is generally determined by a healthcare professional based on the specific condition and the patient's course of treatment.


Q: Can Demil interact with common flu or cold medicines?

The official label does not list 'flu or cold medicines' as a single group. However, it contains warnings about combining Demil with sympathomimetic agents, such as certain decongestants found in some cold medicines. Combining these types of medications can potentially lead to increased side effects.


Q: Is Demil used for anything other than what is listed in the official documents?

Official documents define the specific approved indications for which the drug has been licensed by regulatory agencies. Any use beyond these evaluated and approved indications, often referred to as 'off-label' use, is not detailed or supported by the manufacturer's official labeling.


Q: What is the typical length of time a person stays on Demil?

Demil is prescribed for several long-term health conditions, and some clinical studies have evaluated continuous use for periods exceeding two years. The duration of use is not fixed. The duration of use is generally determined by a healthcare professional based on the specific condition being managed and the patient's needs.


Q: Where can I find official, non-commercial information about Demil's research?

Official, non-commercial information about Demil's research and regulatory status can be found on websites maintained by government regulatory bodies. Examples include the US Food and Drug Administration (FDA) DailyMed and information portals provided by the National Institutes of Health (NIH).


Q: Why is Demil sometimes confused with a different drug that treats similar conditions?

Demil is a brand name for the active ingredient Bromocriptine, which is a dopamine receptor agonist. Confusion can sometimes arise because the brand name 'Demil' has been historically or contextually associated with a different active ingredient, Diphemanil Methylsulfate, which is an anticholinergic agent with a distinct mechanism of action.


Q: Does Demil require any special monitoring by a doctor while in use?

Yes, due to the drug's properties, the official label advises careful patient monitoring. This includes monitoring for signs of cardiovascular risk, changes in blood pressure, and potential psychological side effects. Certain laboratory values are also monitored depending on the indication being managed.


Q: Does Demil contain gluten or common allergens like nuts?

The official label lists the drug's inactive ingredients, which typically include components like lactose and magnesium stearate. Standardized information regarding the presence of common allergens like gluten or nuts is not explicitly required across all labels. For this reason, it is common practice for individuals with severe allergies to review the specific product's complete inactive ingredients list.


Q: What happens if I accidentally use more Demil than intended?

In cases of accidental overuse or if more than the prescribed amount is ingested, official regulatory information strongly advises immediately seeking medical assistance. Official guidance indicates that contact with a poison control center or emergency services is warranted immediately.


Q: Is Demil known to cause weight gain or weight loss?

Significant weight gain or weight loss is not listed among the most commonly reported adverse events in the official label. However, the drug's effects on appetite are noted in the safety data, and weight changes may be monitored as an outcome in clinical studies depending on the condition being treated.


Q: Are skin reactions a recognized side effect of Demil?

Official safety data gathered through post-marketing experience includes reports of various skin reactions. These reported dermatologic events include allergic skin reactions, skin rash, and mottling of the skin. Such events are generally reported as rare or with an unknown frequency.


Q: Do you need a special prescription or authorization to get Demil?

Yes, Demil is classified by regulatory authorities as a human prescription drug. This means it can only be legally dispensed after being prescribed by a licensed healthcare provider.


Q: Is Demil widely available globally, or is it restricted to certain regions?

Demil (Bromocriptine) has been reviewed and registered by multiple major drug regulatory bodies across different global regions, including North America, Europe, and Australia. This suggests that the medication is generally available, although access and specific branding are controlled locally by each region's health authorities.

How should Demil be stored and disposed of?

How to Store and Dispose of Demil (Bromocriptine)

Official regulatory information defines specific conditions for storing and discarding Demil tablets to maintain drug integrity and safety.

Demil must be stored at room temperature, which is typically defined as 20 C to 25 C (68 F to 77 F). Storage areas must not exceed 25 C. The medication requires protection from light and excess moisture; therefore, it must be kept in the original container and the container must be tightly closed.


Key Storage and Disposal Constraints

Constraint Type Regulatory Requirement
Temperature Do not store above 25 C; do not freeze.
Access Must be kept out of the sight and reach of children.
Disposal Dispose of unused or expired product strictly according to local regulations (do not flush down the toilet).

The product should not be used past the expiry date and must be discarded responsibly when no longer needed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Demil found in:

A-Z Index: